CHF10067 starting dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05513950 (ClinicalTrials.gov) | January 25, 2023 | 17/8/2022 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF | A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Intravenous Monoclonal Antibody (mAB) After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: CHF10067 starting dose;Biological: CHF10067 intermediate dose;Biological: CHF10067 high dose;Drug: Placebo | Chiesi Farmaceutici S.p.A. | NULL | Recruiting | 40 Years | 80 Years | All | 24 | Phase 1 | United Kingdom |